Earlier this month, Vivus Inc. (NASDAQ:VVUS) said it filed a patent-infringement lawsuit against Actavis PLC ( ACT ) alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 3.97% in last session and finished the day at $5.50. Traded volume was 4.47million shares in the last session and the average volume of the stock remained 3.04million … Continue reading Health Stocks to Watch: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Eli Lilly (NYSE:LLY)